Jazz Pharmaceuticals (NASDAQ:JAZZ) Coverage Initiated at Deutsche Bank Aktiengesellschaft

Equities researchers at Deutsche Bank Aktiengesellschaft assumed coverage on shares of Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) in a research note issued to investors on Tuesday, Marketbeat Ratings reports. The firm set a "buy" rating and a $152.00 price target on the specialty pharmaceutical company's stock. Deutsche Bank Aktiengesellschaft's price objective points to a potential upside of 34.67% from the stock's current price.

A number of other equities analysts also recently commented on the stock. Wall Street Zen downgraded shares of Jazz Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Thursday, May 15th. Robert W. Baird dropped their target price on shares of Jazz Pharmaceuticals from $167.00 to $155.00 and set an "outperform" rating on the stock in a research note on Wednesday, May 7th. Morgan Stanley dropped their target price on shares of Jazz Pharmaceuticals from $183.00 to $166.00 and set an "overweight" rating on the stock in a research note on Wednesday, May 7th. Piper Sandler restated an "overweight" rating and issued a $147.00 target price (down from $176.00) on shares of Jazz Pharmaceuticals in a research note on Wednesday, May 7th. Finally, Royal Bank Of Canada dropped their target price on shares of Jazz Pharmaceuticals from $182.00 to $172.00 and set an "outperform" rating on the stock in a research note on Wednesday, May 7th. Two analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $181.71.

Jazz Pharmaceuticals Trading Down 1.7%

Jazz Pharmaceuticals stock traded down $1.99 during midday trading on Tuesday, reaching $112.87. The stock had a trading volume of 550,586 shares, compared to its average volume of 831,998. The company has a quick ratio of 2.97, a current ratio of 3.38 and a debt-to-equity ratio of 1.28. Jazz Pharmaceuticals has a 52-week low of $95.49 and a 52-week high of $148.06. The firm has a market cap of $6.83 billion, a price-to-earnings ratio of 15.05, a price-to-earnings-growth ratio of 5.80 and a beta of 0.32. The company has a fifty day moving average of $108.83 and a 200 day moving average of $118.35.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share for the quarter, missing analysts' consensus estimates of $4.65 by ($2.97). Jazz Pharmaceuticals had a return on equity of 26.62% and a net margin of 11.86%. The firm had revenue of $897.84 million during the quarter, compared to analysts' expectations of $984.16 million. During the same period last year, the company earned $2.68 earnings per share. The business's revenue for the quarter was down .5% compared to the same quarter last year. On average, analysts anticipate that Jazz Pharmaceuticals will post 16.96 earnings per share for the current fiscal year.

Insider Activity at Jazz Pharmaceuticals

In other news, Director Seamus Mulligan acquired 100,000 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Friday, May 9th. The stock was purchased at an average price of $98.26 per share, for a total transaction of $9,826,000.00. Following the purchase, the director directly owned 100,000 shares in the company, valued at $9,826,000. The trade was a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Bruce C. Cozadd sold 1,000 shares of the business's stock in a transaction that occurred on Thursday, May 1st. The stock was sold at an average price of $116.35, for a total transaction of $116,350.00. Following the sale, the chief executive officer directly owned 439,307 shares in the company, valued at approximately $51,113,369.45. This represents a 0.23% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 2,500 shares of company stock valued at $277,930. 4.30% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Focus Partners Wealth acquired a new position in Jazz Pharmaceuticals during the 4th quarter valued at approximately $551,000. CX Institutional acquired a new stake in shares of Jazz Pharmaceuticals in the first quarter worth $4,316,000. Envestnet Portfolio Solutions Inc. increased its stake in shares of Jazz Pharmaceuticals by 38.9% in the first quarter. Envestnet Portfolio Solutions Inc. now owns 4,369 shares of the specialty pharmaceutical company's stock worth $542,000 after acquiring an additional 1,223 shares during the period. Atria Investments Inc increased its stake in shares of Jazz Pharmaceuticals by 19.5% in the fourth quarter. Atria Investments Inc now owns 2,732 shares of the specialty pharmaceutical company's stock worth $336,000 after acquiring an additional 445 shares during the period. Finally, GAMMA Investing LLC increased its stake in shares of Jazz Pharmaceuticals by 63.7% in the first quarter. GAMMA Investing LLC now owns 1,015 shares of the specialty pharmaceutical company's stock worth $126,000 after acquiring an additional 395 shares during the period. Institutional investors and hedge funds own 89.14% of the company's stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.